8th February 2025

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: Update on USFDA Inspection at Company's manufacturing facility in Virgonagar, Bengaluru, India

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated 13th November, 2024, regarding the routine current Good Manufacturing Practices (cGMP) inspection at Company's manufacturing facility in Virgonagar, Bengaluru, India, between 7th – 13th November, 2024, we hereby notify that the United States Food and Drug Administration (USFDA) vide communication dated Friday, 7th February, 2025 (9.03 PM IST) has classified the above referred inspection as Voluntary Action Indicated ("VAI").

Thanking you,
Yours faithfully,
For Cipla Limited

RAJENDRA KUMAR CHOPRA
Digitally signed by RAJENDRA KUMAR CHOPRA
Date: 2025.02.08 [illegible]05'30'

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode